Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Pricing
Rankings
For Publishers
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Pricing
Rankings
For Publishers
Log In
Start Free Trial
ADIL I. DAUD
Sign up to set email alerts
844
Publications
37,306
Citation Statements Received
12,240
Citation Statements Given
How they've been cited
50,390
1,326
35,853
127
How they cite others
15,537
575
11,632
33
Affiliations
University of California, San Francisco
,
Moffitt Cancer Center
Publications
Order By: Most citations
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert
1
,
Schachter
2
,
Long
3
et al.
2015
N Engl J Med
Abstract
Show
6,202
115
4,142
19
Get article
Add to collection
Cite
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid
1
,
Robert
2
,
DAUD
3
et al.
2013
N Engl J Med
Abstract
Show
3,436
32
2,485
3
3
Get article
Add to collection
Cite
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Flaherty
1
,
Infante
2
,
DAUD
3
et al.
2012
N Engl J Med
Abstract
Show
2,862
45
2,149
4
Get article
Add to collection
Cite
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Robert
1
,
Ribas
2
,
Wolchok
3
et al.
2014
The Lancet
1,792
32
1,237
1
Get article
Add to collection
Cite
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
Broz
1
,
Binnewies
2
,
Boldajipour
3
et al.
2014
Cancer Cell
Abstract
Show
1,328
65
1,192
1
1
Get article
Add to collection
Cite
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas
1
,
Puzanov
2
,
Dummer
3
et al.
2015
The Lancet Oncology
Abstract
Show
1,608
43
1,078
4
Get article
Add to collection
Cite
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Robert
1
,
Ribas
2
,
Schachter
3
et al.
2019
The Lancet Oncology
1,237
45
1,028
6
Get article
Add to collection
Cite
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Nghiem
1
,
Bhatia
2
,
Lipson
3
et al.
2016
N Engl J Med
Abstract
Show
1,319
19
972
2
Get article
Add to collection
Cite
1
2
3